Key facts
- Daraxonrasib is the first drug to push median survival beyond one year in a Phase 3 pancreatic cancer trial.
- Daraxonrasib cut the risk of death by 60% in the trial.
- Patients on daraxonrasib lived a median of 13.2 months, compared to 6.7 months on chemotherapy.
- Daraxonrasib targets a mutated protein common in pancreatic cancer.
- The drug is administered as a once-daily pill.
- Daraxonrasib improved quality of life for trial participants.
- Side effects noted include rash and mouth sores.
- Revolution Medicines plans regulatory filings for daraxonrasib.
- Researchers are considering earlier use and pre-surgical application of daraxonrasib.
Revolution Medicines has announced a major success for its pancreatic cancer drug, daraxonrasib, in a Phase 3 trial. The drug is the first to push median survival beyond one year for patients with advanced pancreatic cancer. In the trial, daraxonrasib cut the risk of death by 60%, with patients achieving a median survival of 13.2 months compared to 6.7 months for those receiving chemotherapy. The drug targets a mutated protein common in the disease and is administered as a once-daily pill.
Beyond extending survival, daraxonrasib also showed improvements in the quality of life for participants. However, some side effects were noted, including rash and mouth sores. Researchers are considering further studies to explore earlier use of the drug and its application pre-surgically. Revolution Medicines plans to proceed with regulatory filings based on these positive outcomes.
This development marks a significant advancement in the treatment of pancreatic cancer, a disease with historically poor prognoses. The targeted approach of daraxonrasib, focusing on specific genetic mutations, represents a shift towards more personalized medicine in oncology. The drug's ability to nearly double survival time and improve quality of life offers new hope for patients facing this challenging diagnosis.